INTESTIFIX 001
Sponsors
Klinikum Der Universitat Munchen AöR, Universitaetsklinikum Heidelberg AöR, Universitaetsklinikum Aachen AöR, Goethe University Frankfurt
Conditions
Crohn's diseaseHepatocellular carcinomaInfections with multidrug-resistant EnterobacteriaceaeRecurrent urinary tract infections (rUTI)cirrhosis and ascites
Phase 1
Phase 2
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blind Phase II trial (FLORA)
RecruitingCTIS2023-506887-15-00
Start: 2025-07-14Target: 48Updated: 2026-01-22
Encapsulated Fecal Microbiota Transfer to Treat Immune Activation in Patients with Cirrhosis and Ascites (TransImmune) – A randomized, double-blind, placebo-controlled phase IIa clinical pilot study
RecruitingCTIS2023-507790-18-00
Start: 2025-08-01Target: 24Updated: 2026-01-12
A Randomized controlled open-label phase II trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal microbiota transfer products with or without an individualized donor selection approach in decolonizing carriers of multi-drug resistant Enterobacteriaceae (RESET-MDR)
RecruitingCTIS2024-519748-34-00
Start: 2026-01-23Target: 76Updated: 2025-10-09
Fecal microbiota transfer for the secondary prevention of recurrent urinary tract infections in premenopausal women: a phase II trial (FEMITRANS)
Not yet recruitingCTIS2025-520452-28-00
Target: 24Updated: 2026-01-07